Journal
CLINICAL INFECTIOUS DISEASES
Volume 56, Issue 11, Pages 1629-1636Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cit074
Keywords
peginterferon; ribavirin; chronic hepatitis C treatment; adverse events
Categories
Funding
- Intramural Divisions of the National Institute of Diabetes and Digestive and Kidney Diseases
- National Cancer Institute of the National Institutes of Health
Ask authors/readers for more resources
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
